APA

Meulendijks D., Henricks L. M., van Kuilenburg A. B. P., Jacobs B. A. W., Aliev A., Rozeman L., Meijer J., Beijnen J. H., de Graaf H., Cats A. & Schellens J. H. M. (20170606). Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. : Cancer chemotherapy and pharmacology.

Chicago

Meulendijks Didier, Henricks Linda M, van Kuilenburg André B P, Jacobs Bart A W, Aliev Abidin, Rozeman Lisette, Meijer Judith, Beijnen Jos H, de Graaf Hiltje, Cats Annemieke and Schellens Jan H M. 20170606. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. : Cancer chemotherapy and pharmacology.

Harvard

Meulendijks D., Henricks L. M., van Kuilenburg A. B. P., Jacobs B. A. W., Aliev A., Rozeman L., Meijer J., Beijnen J. H., de Graaf H., Cats A. and Schellens J. H. M. (20170606). Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. : Cancer chemotherapy and pharmacology.

MLA

Meulendijks Didier, Henricks Linda M, van Kuilenburg André B P, Jacobs Bart A W, Aliev Abidin, Rozeman Lisette, Meijer Judith, Beijnen Jos H, de Graaf Hiltje, Cats Annemieke and Schellens Jan H M. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. : Cancer chemotherapy and pharmacology. 20170606.